We use cookies to ensure that we give you the best experience on our website. By continuing to browse this repository, you give consent for essential cookies to be used. You can read more about our Privacy and Cookie Policy.

Durham Research Online
You are in:

New active leads for tuberculosis booster drugs by structure-based drug discovery.

Tatum, Natalie J and Liebeschuezt, John and Cole, Jason C. and Frita, Rosangela and Herledan, Adrien and Baulard, Alain and Willand, Nicolas and Pohl, Ehmke (2017) 'New active leads for tuberculosis booster drugs by structure-based drug discovery.', Organic & biomolecular chemistry., 15 (48). pp. 10245-10255.


The transcriptional regulator EthR from Mycobacterium tuberculosis, a member of the TetR family of prokaryotic homo-dimeric transcriptions factors, controls the expression of the mycobacterial mono-oxygenase EthA. Due to the fact that EthA is responsible for the bio-activation of the second-line tuberculosis pro-drug ethionamide, EthR inhibitors have been shown to boost drug efficacy by increasing EthA levels. Here, we present a comprehensive in-silico structure-based screening protocol that led to the identification of a number of novel scaffolds of EthR inhibitors. We present biophysical characterization of 85 potential leads, 20 of which showed binding by thermal shift assays. The co-crystal structures of EthR with four new ligands at resolution ranging from 2.1 to 1.4 Å confirm the binding and inactivation mode. The crystal structures include ligands with three new chemical scaffolds that will enable future lead development. Five of the lead compounds showed the desired booster effect with the most promising displaying an EC50 value of 0.76 μM.

Item Type:Article
Full text:(AM) Accepted Manuscript
Download PDF
Publisher Web site:
Date accepted:01 November 2017
Date deposited:09 November 2017
Date of first online publication:01 November 2017
Date first made open access:01 November 2018

Save or Share this output

Look up in GoogleScholar